1. Home
  2. NKTR vs ELA Comparison

NKTR vs ELA Comparison

Compare NKTR & ELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKTR
  • ELA
  • Stock Information
  • Founded
  • NKTR 1990
  • ELA 1965
  • Country
  • NKTR United States
  • ELA United States
  • Employees
  • NKTR N/A
  • ELA N/A
  • Industry
  • NKTR Biotechnology: Pharmaceutical Preparations
  • ELA Consumer Specialties
  • Sector
  • NKTR Health Care
  • ELA Consumer Discretionary
  • Exchange
  • NKTR Nasdaq
  • ELA Nasdaq
  • Market Cap
  • NKTR 160.4M
  • ELA 156.2M
  • IPO Year
  • NKTR 1994
  • ELA N/A
  • Fundamental
  • Price
  • NKTR $0.59
  • ELA $6.61
  • Analyst Decision
  • NKTR Strong Buy
  • ELA Strong Buy
  • Analyst Count
  • NKTR 6
  • ELA 1
  • Target Price
  • NKTR $4.92
  • ELA $9.00
  • AVG Volume (30 Days)
  • NKTR 2.3M
  • ELA 19.2K
  • Earning Date
  • NKTR 05-08-2025
  • ELA 05-07-2025
  • Dividend Yield
  • NKTR N/A
  • ELA N/A
  • EPS Growth
  • NKTR N/A
  • ELA 15.15
  • EPS
  • NKTR N/A
  • ELA 0.28
  • Revenue
  • NKTR $87,248,000.00
  • ELA $188,774,278.00
  • Revenue This Year
  • NKTR N/A
  • ELA $6.47
  • Revenue Next Year
  • NKTR N/A
  • ELA $7.42
  • P/E Ratio
  • NKTR N/A
  • ELA $23.44
  • Revenue Growth
  • NKTR N/A
  • ELA 14.19
  • 52 Week Low
  • NKTR $0.43
  • ELA $4.20
  • 52 Week High
  • NKTR $1.93
  • ELA $7.88
  • Technical
  • Relative Strength Index (RSI)
  • NKTR 39.04
  • ELA 53.67
  • Support Level
  • NKTR $0.57
  • ELA $6.37
  • Resistance Level
  • NKTR $0.81
  • ELA $6.82
  • Average True Range (ATR)
  • NKTR 0.06
  • ELA 0.32
  • MACD
  • NKTR -0.01
  • ELA -0.01
  • Stochastic Oscillator
  • NKTR 7.48
  • ELA 63.33

About NKTR Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

Share on Social Networks: